[HTML][HTML] Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral methotrexate and topical trametinib
JAAD Case Reports, 2023•Elsevier
Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral methotrexate and
topical trametinib - ScienceDirect Skip to main contentSkip to article Elsevier logo Journals &
Books Help Search My account Sign in View PDF Download full issue Search ScienceDirect
Elsevier JAAD Case Reports Volume 39, September 2023, Pages 74-77 JAAD Case Reports
Case report Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral
methotrexate and topical trametinib Author links open overlay panel Christopher J. Fay BA a …
topical trametinib - ScienceDirect Skip to main contentSkip to article Elsevier logo Journals &
Books Help Search My account Sign in View PDF Download full issue Search ScienceDirect
Elsevier JAAD Case Reports Volume 39, September 2023, Pages 74-77 JAAD Case Reports
Case report Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral
methotrexate and topical trametinib Author links open overlay panel Christopher J. Fay BA a …
Discussion
We report a novel case of CRDD that recurred following surgical excision and was refractory to numerous lines of therapy, including ILTAC monotherapy, but ultimately responded to the addition of topical MEK inhibition and methotrexate.
Elsevier
